3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Genital Diseases, Male
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostate Cancer Non-Metastatic
×
darolutamide
×
Clear all
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA